Press Releases

Date	Title	PDF Version
Jul 27, 2017	Alexion Reports Second Quarter 2017 Results
Jul 11, 2017	Alexion to Report Second Quarter 2017 Results and Strategic Update on Thursday, July 27, 2017
Jul 05, 2017	Alexion Reaches Funding Agreement with NICE and NHS England for Strensiq® (asfotase alfa) for Patients with Pediatric-onset Hypophosphatasia (HPP)
Jun 23, 2017	Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union
Jun 13, 2017	Alexion Names Paul Clancy Chief Financial Officer
Jun 01, 2017	Alexion Announces Additions to Executive Leadership Team
May 30, 2017	Alexion to Present at Upcoming Investor Conferences
May 23, 2017	Alexion Announces Executive Leadership Changes
May 16, 2017	Rady Children's Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns
May 15, 2017	Long-term Data Confirm Benefits of Treatment with Strensiq® (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years

Search